Current treatment status-Undergoing active treatment-Progressive despite several lines of treatment - Page 3 of 23 Posts on Medivizor
Navigation Menu

Current treatment status-Undergoing active treatment-Progressive despite several lines of treatment Posts on Medivizor

Idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia in a real life setting

Idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia in a real life setting

Posted by on Apr 24, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the effectiveness of idelalisib (Zydelig) and rituximab (Rituxan) in patients with relapsed/refractory (r/r) chronic lymphocytic leukemia (CLL) in a real-life setting.  This study concluded that this treatment in a real-life setting was just as effective as in a clinical trial...

Read More

Is VD-PACE and immunotherapy a good salvage therapy for relapsed/refractory multiple myeloma?

Is VD-PACE and immunotherapy a good salvage therapy for relapsed/refractory multiple myeloma?

Posted by on Apr 11, 2021 in Multiple Myeloma | 0 comments

In a nutshell The aim of this study was to evaluate if the VD-PACE (bortezomib, dexamethasone, cisplatin, doxorubicin, cyclophosphamide, etoposide) regimen in combination with immunotherapy was effective as a salvage therapy for patients with relapsed or refractory (r/r) multiple myeloma (MM). The study found this salvage therapy option...

Read More

How effective is umbralisib as treatment for patients with relapsed or refractory low-grade lymphoma?

How effective is umbralisib as treatment for patients with relapsed or refractory low-grade lymphoma?

Posted by on Apr 11, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell The authors assessed the safety and effectiveness of umbralisib (Ukoniq) in patients with relapsed or refractory (r/r) indolent (low-grade) non-Hodgkin lymphoma (iNHL).   The study concluded that umbralisib was well tolerated and effective for patients with r/r iNHL. Some background iNHL is a slow-growing cancer of...

Read More

Comparing ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukemia

Comparing ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukemia

Posted by on Apr 11, 2021 in Leukemia | 0 comments

In a nutshell This study investigated the safety and effectiveness of adding ublituximab (TG-1101) to ibrutinib (Imbruvica) treatment for patients with relapsed or refractory (r/r) chronic lymphocytic leukemia (CLL). The data showed that adding ublituximab to ibrutinib significantly improved the overall response rate compared to ibrutinib alone...

Read More

How effective is involved field radiotherapy after autologous hematopoietic stem-cell transplantation in patients with high-risk relapsed/refractory lymphoma?

How effective is involved field radiotherapy after autologous hematopoietic stem-cell transplantation in patients with high-risk relapsed/refractory lymphoma?

Posted by on Apr 4, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell The authors assessed the safety and efficacy of involved-field radiotherapy (IFRT) after autologous hematopoietic stem-cell transplantation (ASCT) in patients with high-risk relapsed/refractory (r/r) lymphoma. The study found that IFRT given soon after ASCT provided durable responses and was well tolerated in these patients. Some...

Read More

Is olmutinib effective in treating T790M-positive unresponsive non-small cell lung cancer?

Is olmutinib effective in treating T790M-positive unresponsive non-small cell lung cancer?

Posted by on Apr 3, 2021 in Lung cancer | 0 comments

In a nutshell This article looked at the use of olmutinib (Olita) in the treatment of T790M-positive non-small cell lung cancer (NSCLC) that was previously unresponsive to a tyrosine kinase inhibitor (TKI). The authors concluded that olmutinib had clinical activity and manageable side effects in these patients. Some background NSCLC accounts for...

Read More

Combining venetoclax and navitoclax with chemotherapy in patients with relapsed/refractory acute lymphoblastic leukemia and lymphoblastic lymphoma

Combining venetoclax and navitoclax with chemotherapy in patients with relapsed/refractory acute lymphoblastic leukemia and lymphoblastic lymphoma

Posted by on Mar 28, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of venetoclax (Venclexta) and low-dose navitoclax (ABT-263) in combination with chemotherapy in patients with relapsed/refractory (r/r) acute lymphoblastic leukemia (ALL).  This study concluded that this treatment option was well tolerated and...

Read More

Evaluating the effectiveness of BGD therapy in relapsed/refractory Hodgkin lymphoma

Evaluating the effectiveness of BGD therapy in relapsed/refractory Hodgkin lymphoma

Posted by on Mar 28, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of the BGD (bendamustine, gemcitabine, and dexamethasone) regimen in patients with previously treated Hodgkin lymphoma (HL). This study concluded that BGD is well-tolerated and highly effective in these patients.  Some background Hodgkin lymphoma (HL) is a cancer that...

Read More

Improved outcomes for relapsed/refractory multiple myeloma patients treated with daratumumab.

Improved outcomes for relapsed/refractory multiple myeloma patients treated with daratumumab.

Posted by on Feb 27, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the effect of daratumumab (Darzalex)-based treatments on sustained minimal residual disease (MRD) negativity and outcomes in patients with relapsed/refractory (RR) multiple myeloma (MM). The data showed that treatments including daratumumab led to sustained MRD negativity and improved outcomes in these...

Read More

Evaluating the combination of brentuximab vedotin with ipilimumab and nivolumab in relapsed/refractory Hodgkin lymphoma.

Evaluating the combination of brentuximab vedotin with ipilimumab and nivolumab in relapsed/refractory Hodgkin lymphoma.

Posted by on Feb 7, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated the effectiveness and safety of combination regimens of brentuximab vedotin (BV; Adcetris), ipilimumab (Yervoy), and nivolumab (Opdivo) in patients with relapsed/refractory Hodgkin lymphoma (HL). The data showed that the treatment combinations had promising effectiveness and manageable side effects. Some background...

Read More

Looking for patients with HER-2 positive advanced breast cancer to trial an experimental treatment.

Looking for patients with HER-2 positive advanced breast cancer to trial an experimental treatment.

Posted by on Jan 28, 2021 in Breast cancer | 0 comments

In a nutshell This trial is aiming to examine the safety and effectiveness of an experimental treatment called BPX-063, a CAR-T cell treatment, in patients with advanced HER-2 positive breast cancer. The main outcomes to be measured are the maximum tolerated dose of BPX-603 and the antitumor activity. This trial is being carried out across the...

Read More

Inotuzumab ozogamicin in patients with hard to treat, Philadelphia chromosome-positive acute lymphoblastic leukemia

Inotuzumab ozogamicin in patients with hard to treat, Philadelphia chromosome-positive acute lymphoblastic leukemia

Posted by on Dec 26, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the effectiveness of inotuzumab ozogamicin (InO; Besponsa) in patients with Philadelphia chromosome-positive (Ph+) relapsed/refractory (r/r) acute lymphoblastic leukemia (ALL). This study concluded that this treatment is a good option for these patients.  Some background Ph chromosome...

Read More